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Abstract
There is a long-standing controversy on whether membrane lipids or proteins are the target for general anesthetics. The
plasma membrane-associated Ca2-ATPase of synaptosomes has recently been established as a model system for general
anesthesia, the protein interior being the proposed target site (M.M. Lopez, D. Kosk-Kosicka, J. Biol. Chem. 270 (1995)
28239^28245). Multiple-site kinetics is now applied as a mechanistic tool to analyze inhibition by organic solvents and
general anesthetics. A close fit to the experimental data points was achieved using the complex equations for a competitive
displacement of lipid activators from multiple sites on the protein surface. Inhibitor dissociation constants were about
1.6U105-fold higher than the microscopic lipid dissociation binding constants that are derived here for the first time. Binding
of lipid therefore is by 37.1 kcal/mole favored over that of the tested inhibitors. The latter are nevertheless effective because
in the model used displacement of only few of the lipid solvation molecules cause complete inhibition. The lipid/protein
interface rather than protein or lipid alone appeared to be the anesthetic target site. ß 1998 Elsevier Science B.V. All rights
reserved.
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1. Introduction
There is a long-standing controversy on whether
membrane lipids or proteins are the target for gen-
eral anesthetics [1^3]. The displacement of solvation
lipids by anesthetics has also been considered as a
hypothetical mechanism [1,4]. The lipid/protein inter-
face is a possible target site because many membrane
enzymes [5,6] and gated channel proteins such as the
nicotinic acetylcholine receptor [7,8] require lipids for
activity. Electron spin resonance (ESR) spectroscopy
with spin-labeled lipids appears to be the most ap-
propriate method to directly examine displacement
processes at the lipid/protein interface. However,
such experiments have been stated to be technically
very di⁄cult [8] and have so far been both in favor of
[9,10] and against [11,12] the lipid displacement
mechanism. In view of the lack of adequate physical
methods, multiple-site kinetics is employed here as a
mechanistic tool. The present analysis is based on the
kinetic formalism established previously for lipid-de-
pendent enzymes [5,6] and for the inhibition of mem-
brane enzymes by lipid displacement [13,14]. A re-
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cent stopped-£ow kinetic study of the nicotinic ace-
tylcholine receptor has shown that the cholesterol
activation site is within, or very close to, the lipid/
protein interface [15].
The elementary binding processes at the protein
surface and the basic de¢nitions of the microscopic
lipid activator binding dissociation constant, Kl, and
the microscopic inhibitor binding dissociation con-
stant, Ki, are shown in Fig. 1. Probability factors
have to be introduced when multiple binding sites
are considered [5]. Theoretical modeling [13] and
the analysis of the inhibition of (Na+K)-ATPase
and lactose permease by alcohols [14] have de¢ned
values of kinetic cooperativity that are diagnostic for
the lipid displacement mechanism. The cooperativity
index, I90/I10; should be in the range between 2 and
30, a value of I90/I10 = 81 representing hyperbolic ki-
netics. I90/I10 is the ratio of inhibitor concentrations
leading to 90% and 10% inhibition, respectively. The
present kinetic analysis is based on the idea that
catalytic membrane proteins require a de¢ned num-
ber n of solvation lipid molecules for activity,
although a number a of non-occupied lipid solvation
sites may be tolerated [5].
Inhibition experiments and kinetic modeling are
presented here for the synaptosomal Ca2-ATPase.
Recent publications have established this enzyme as
a model system for general anesthesia [16^18]. The
enzyme is not of direct pharmacological relevance
since the anesthetics were employed an order of mag-
nitude above concentrations used in clinical practice
[19,20]. It was postulated that the hydrophobic pro-
tein interior acts as the anesthetic binding site, in
analogy to the binding of anesthetics to the lipid-
free proteins, myoglobin, hemoglobin and adenylate
kinase [17]. The lipid displacement mechanism was
not considered, but is now examined for organic sol-
vents as well as general anesthetics. For this purpose,
the published assay conditions [16^18] were adopted
for the following strategy of kinetic analysis. (1) Ac-
tivation kinetics: determine Kl for lipid activation of
Ca2-ATPase, using a ¢xed value of n and a ¢tted
value of a. (2) Inhibition kinetics: employ the values
of Kl and a to derive Ki values for anesthetics and
organic solvents. (3) Anesthetic e⁄ciency: derive free
energy di¡erences of the binding of lipid activators
versus anesthetic inhibitors from the numerical val-
ues of Kl and Ki by a standard thermodynamic treat-
ment. Such free energy values are up to now not
available in the literature.
2. Materials and methods
2.1. Synaptosomal plasma membranes
Cortical tissue of fresh pig brain from a Munich
slaughterhouse was homogenized and synaptosomal
plasma membranes were prepared by Ficoll gradient
centrifugation, using published procedures [21]. The
preparation was stored at 380‡C. The lipid to pro-
tein ratio of synaptosomal plasma membranes is
about 1:1 [22]. A uniform lipid molecular mass value
of 800 Da was used for stoichiometric calculations.
Protein was determined by the procedure of Brad-
ford [23].
2.2. Enzyme assays
All assays were carried out in a ¢nal volume of 330
Wl with use of 5 Wg total plasma membrane protein.
Ca2-ATPase activity was determined as described
[18] without addition of calmodulin. Typical values
of speci¢c activity were 5^7 nkat/mg protein regard-
less of whether calmodulin (Sigma Cat. No. P1915)
was added or not. Control values (subtracted) were
determined in the presence of 1 mM EGTA. Liber-
ated free phosphate was measured colorimetrically
[24]. (Na+K)-ATPase activity was determined as
Fig. 1. Schematic view of the binding equilibria of lipid activa-
tor (a) and inhibitor (b) and de¢nition of the elementary bind-
ing dissociation constants.
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described [18] using 72 mM histidine, 1.4 mM
EGTA, pH 7.4, as test bu¡er. Control values (sub-
tracted) were determined in the presence of 1 mM
ouabain. Typical values of speci¢c activity were 20^
30 nkat/mg protein. Mg2-ATPase was determined
as described [18] using 69 mM Tris-maleate, 1.4 mM
EGTA, pH 7.4, as test bu¡er. Control values (sub-
tracted) were determined without addition of Mg2.
Typical values of speci¢c activity were between 13
and 16 nkat/mg protein.
Ca2-ATPase activity was reduced by 45% upon
inclusion of 1 mM vanadate. About 50% vanadate
inhibition has previously been reported for rat cere-
brum synaptosomal Ca2-ATPase [25]. Highly puri-
¢ed plasma membrane Ca2-ATPase is known to
show maximally 80% inhibition by vanadate [26].
As in the previous studies [16^18,21] addition of
vanadate was not made in the inhibition experiments
to be described. The present Ca2-ATPase activity
appears to di¡er from synaptosomal ecto-ATPases
that are equally well activated by Ca2 and Mg2
and that are insensitive to vanadate [25,27]. The
pig synaptosomal vesicles used here are known to
contain plasma membrane Ca2- and Mg2-ATPases
[21].
2.3. Inhibition experiments
The inhibitors were added to the assay mixtures
(minus ATP) by means of Hamilton syringes. En-
zyme assays were carried out in gas-tight HPLC vials
carrying a septum. Alcohol concentrations were cal-
culated from the added amounts. The other inhibi-
tors were added in bu¡er that had been equilibrated
with excess inhibitor. The following literature values
[28] for aqueous saturation concentrations were
used: chloroform, 66.6 mM; halothane: 17 mM; iso-
£urane: 15 mM; en£urane: 15 mM. Corrections of
approx. 10% were made for losses into the vial head
space. Justi¢cation for the procedures used here
comes from the agreement of the present inhibition
results with the previously reported data [16^20]
where aqueous anesthetic concentrations had been
calibrated by gas chromatography. After preincubat-
ing the present inhibitor-containing assay mixtures
for 15 min at 37‡C, the enzyme reactions were in
all cases started by addition of ATP (dissolved in
assay bu¡er) to a ¢nal concentration of 3 mM.
2.4. Data treatment
Three to nine replicates of all experiments were
performed and mean values þ S.D. determined. All
calculations, including non-linear regression were
carried out using Sigma Plot software.
3. Results
3.1. Kinetics of lipid activation
No precise lipid activation data are available for
the synaptosomal Ca2-ATPase, but this is the case
for the structurally related plasma membrane-associ-
ated Ca2-ATPase from erythrocytes [29]. An initial
kinetic analysis of these activation data had shown
that the cooperativity index, L90/L10, was around 10
[6], and therefore within the range of L90/L10 between
2 and 30 that is typical for activation by lipid solva-
tion [5,6]. L90/L10 is the ratio of lipid concentrations
required to reach 90% and 10%, respectively, of max-
imum activation. The deduction of Kl values (see
Fig. 1 for de¢nition) requires knowledge of the total
number n of lipid molecules solvating the enzyme
molecule [30]. This value is not known for plasma
membrane-associated Ca2-ATPases, but the model-
ing of lipid-dependent enzymes generally is not very
sensitive to the exact value of n [30]. Therefore, the
value of n = 60 that has been determined for
(Na+K)-ATPases by ESR spectroscopy [31] is
adopted here in view of protein chemical similarities
between plasma membrane Ca2- and (Na+K)-
ATPases [32]. The full rate equation of [5] was
used. The non-linear regression analysis of activation
by phosphatidylserine (Fig. 2A) led to an optimal
value of 1 for the maximum number (a) of vacant
lipid solvation sites that are tolerated by the enzyme.
Values between 1 and 5 have previously been ob-
tained for dog¢sh (Na+K)-ATPase [30]. A satis-
factory ¢t was reached with a lipid binding dissocia-
tion constant of Kl = 0.16 nmoles lipid per Wg puri¢ed
protein. With a molecular mass value of 280 kDa for
the active Ca2-ATPase dimer [21,32], this corre-
sponds to Kl = 45 lipid molecules per enzyme mole-
cule (the dimension used previously [13]). Similar Kl
values were obtained for the other lipid activators
tested with erythrocyte Ca2-ATPase (phosphatidic
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acid, phosphatidylinositol, cardiolipin [29]). These
values appeared to be too high when compared to
the common value of Kl = 3.8 þ 1.4 lipid molecules
per enzyme molecule that has been derived from lipid
activation curves of dog¢sh (Na+K)-ATPase, sar-
coplasmic reticulum Ca2-ATPase and yeast and bo-
vine mitochondrial cytochrome oxidases (unpub-
lished results). The latter value corresponds to
Kl = 0.014 nmoles lipid per Wg puri¢ed protein. The
reason for the elevated Kl value of Fig. 2A is not
clear. Lipid concentrations of up to 60 nmoles per
Wg puri¢ed protein were employed [29], but only
about 1^1.3 nmoles lipid per Wg protein are present
Fig. 3. Inhibition of the Mg2-, (Na+K)- and Ca2-ATPase
activities of a pig synaptosomal plasma membrane preparation
by chloroform. Relative velocity (v/V) is plotted versus concen-
tration of chloroform (mM).
Fig. 2. Kinetic modeling of plasma membrane Ca2-ATPases.
(A) Activation of the erythrocyte enzyme by phosphatidylserine.
(B) Inhibition of the pig synaptosomal enzyme by chloroform.
In order to be consistent with the published activation data
[29], kinetic constants are given in units of nmol lipid or inhibi-
tor per Wg puri¢ed protein. Relative velocity is plotted as the
ratio of actual over maximal velocity, v/V. Lipid activation was
calculated using the full rate equation of [5] with values of
n = 60 and a = 1, and using the published experimental data
points (a) stimulation by phosphatidylserine [29]. A relative ve-
locity of 0.98 (D) provided the starting point to calculate the
inhibition curve in panel B. The values of n, a, and Kl from the
activation curve were used to ¢t the experimental data points
(b) for inhibition by chloroform. For the comparison with pan-
el A, the millimolar inhibitor concentration unit of Table 1 was
converted to the dimension of nmoles inhibitor/Wg puri¢ed pro-
tein as follows. The amount of membrane protein used (5 Wg)
was divided by 300 in order to obtain the equivalent amount of
puri¢ed Ca2-ATPase protein. Puri¢cation factors of about 300
have been reported for both the erythrocyte [29] and the synap-
tosomal [21] plasma membrane Ca2-ATPase. Next, the nmoles
solvent or anesthetic were calculated from molarity in the test
volume of 330 Wl. One millimolar concentration unit corre-
sponded to 2.1U104 nmoles inhibitor/Wg puri¢ed protein. The
inhibition curve and the derived Ki value are shown for the
higher Kl value. The same ratio of Ki/Kl was obtained for both
Kl values. The full rate equation of [5] was used, replacing Kl
by KlP= KlU(1+[I]/Ki) (cf. [13]).
6
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in plasma membranes from erythrocytes [33] and
synaptosomes [22].
3.2. Kinetics of inhibition
When the three basic ATPase activities of synap-
tosomal membranes were tested in the presence of
organic solvents, Ca2-ATPase activity was inhibited
much more than the (Na+K)-ATPase or Mg2-
ATPase activities. This result is shown for chloro-
form in Fig. 3. The same result was obtained for
hexanol-1, ethanol and butanol-1 (not shown), and
has been reported before for halothane and iso£ur-
ane [18].
The half-maximal inhibitor concentration, I50, and
the cooperativity index, I90/I10 were determined from
the inhibition curves determined for Ca2-ATPase
with a number of solvents and general anesthetics.
These values are summarized in Table 1, and were in
the cases of halothane, iso£urane and en£urane con-
sistent with previously published inhibition curves
[16^19]. There was a rough correlation between anes-
thetic potency and I50. All values of I90/I10 were with-
in the range of 2^30 that is characteristic for the lipid
displacement mechanism [14]. For a quantitative
comparison with the lipid activation data, the milli-
molar concentration values of Table 1 had to be
converted to the dimension of nmoles inhibitor/Wg
puri¢ed protein (Fig. 2B). Curve ¢tting with the val-
ues of n = 60, a = 1 led to Ki values of 0.22c104 and
0.6U105 nmoles inhibitor per Wg puri¢ed protein for
the low Kl and the high Kl value, respectively. The
theoretical inhibition curve obtained for chloroform
is shown in Fig. 2B. The ratio Ki/Kl amounted to
1.6U105 for both Kl values. The general relationship
vG =3RTUln(Ki/Kl) led to a free energy value of
about 37.1 kcal/mole, so that the binding of chloro-
form (as well as of the inhibitors tested) is much less
favorable than that of the lipid activators.
4. Discussion
By ¢rst analyzing published lipid activation data
[29], a numerical framework was generated to also
quantitatively analyze the experimental inhibition
data. It has initially been reported that the inhibition
of the Ca2-ATPase occurs in a range that is relevant
for clinical anesthesia [16^19]. However, this conclu-
sion has subsequently been ascribed to a calculation
error by a factor of 10 [19,20]. The synaptosomal
Ca2-ATPase should therefore be considered as a
model system rather than a physiological target of
general anesthesia.
The Ca2-ATPase had a much higher inhibitor
sensitivity than the (Na+K)- and Mg2-ATPases
of the same synaptosomal membrane preparation
(Fig. 3). A number of processes may be responsible,
one factor being structural di¡erences between the
lipid/protein interfaces of the three tested ATPases.
There may be especially sensitive interfacial sites, and
the assumed identity of all sites [5,6,13,14] is certainly
oversimpli¢ed. Furthermore, the assay conditions
chosen are known to strongly in£uence anesthetic
sensitivity. For example, (Na+K)-ATPase activity
measured as ouabain-sensitive in£ux of 86Rb was
highly sensitive to halothane, while standard
(Na+K)-ATPase enzyme assays were largely in-
sensitive [34]. Ca2-ATPase pumping assays are
also known to be sensitive to clinical concentrations
of inhalational anesthetics [25]. Still, the reason for
the high apparent anesthetic sensitivity of £ux assays
was not clari¢ed. No attempt was made here to mod-
ify the less anesthetic-sensitive assay conditions of
Kosk-Kosicka et al. [16^20], because the present re-
sults were to be compared to the previous data [16^
18]. For the same reason, another possible improve-
ment was not attempted, namely to work with de-
¢ned isoenzyme forms of plasma membrane Ca2-
ATPase [32,35]. Ca2-ATPase isoenzymes may con-
ceivably di¡er in anesthetic sensitivity, as already
Table 1
Kinetic constants for the inhibition of the synaptosomal plasma
membrane-associated Ca2-ATPase activity by organic solvents
and general anesthetics
Inhibitor I50 (mM) I90/I10
Ethanol 360 6.2
Butanol-1 120 4.1
Hexanol-1 7.0 4.4
Chloroform 10.0 4.8
En£urane 2.8 10.3
Iso£urane 1.9 n.d.
Halothane 2.1 4.4
All values were obtained by graphical analysis of inhibition
curves of the type depicted in Fig. 3. n.d., not determined.
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demonstrated for Ca2 and calmodulin dependencies
[35].
A number of n = 60 lipid solvation molecules per
Ca2-ATPase dimer of 280 kDa was assumed here
on the basis of protein chemical similarities between
plasma membrane Ca2-ATPase and (Na+K)-AT-
Pase [32] and of ESR spectroscopic data for the lat-
ter enzyme [31]. The lipid displacement mechanism
was supported by the ¢nding that the cooperativity
index, I90/I10, was in all cases within the character-
istic range of 2^30 [14]. The di¡erences between the
values of L90/L10 of 7.68 (Fig. 2A) and the various
I90/I10 values do not appear to be reliable. The anal-
ysis led to a marked energetic di¡erence between the
binding of lipid and of the tested anesthetics, the
binding of lipid being favored by about 37.1 kcal/
mole. This value may be compared to the much
smaller value (31.0 kcal/mole) for another, more
subtle hydrophobic exchange reaction, namely the
transfer of cholesterol from an isotropic lipid phase
into an anisotropic phospholipid bilayer [36]. At ¢rst
sight, the much less favorable binding of anesthetics
suggests that anesthetic/protein interactions are too
weak to be relevant. On the other hand, functional
membrane proteins in the model used are extremely
vulnerable to lipophilic inhibitors because only a
small number of lipid molecules needs to be dis-
placed for complete inactivation. More precisely,
the threshold number for complete inhibition is
(a+1). The ¢t of the modeled inhibition curve of
Fig. 2B documents that the model used is realistic.
The Ca2-induced enhancement of tryptophan £u-
orescence of the synoptosomal Ca2-ATPase has
been found to be quenched by general anesthetics
[17]. Our analysis of the published quenching curves
led to I50 and I90/I10 values close to those given for
enzyme inhibition in Table 1. The similarity of the
enzyme inhibition and £uorescence quenching curves
for volatile anesthetics has previously been noted and
interpreted in terms of the hydrophobic protein in-
terior serving as the anesthetic binding site [17]. This
hypothesis was based on an apparent analogy to the
binding of anesthetics to the lipid-free proteins, myo-
globin, hemoglobin and adenylate kinase. On the
other hand, the interaction of these anesthetics with
the synaptosomal Ca2-ATPase is driven by entropy,
whereas the interaction of lipophilic compounds with
myoglobin and adenylate kinase is known to be driv-
en by enthalpy [37]. Lipid-free proteins may therefore
not be good model systems for general anesthesia, as
previously also concluded for luciferase on the basis
of insu⁄cient kinetic cooperativity [14].
Interactions at the lipid/protein interface have a
large e¡ect on protein conformation, as shown by
the phenomenon of lipid activation [5^8]. A single
amino acid residue deletion altered the lipid binding
of a K-channel-associated peptide, as indicated by
recent ESR spectroscopic experiments [38]. Similarly,
site-directed mutagenesis or subunit exchange in
gated ion channel proteins indicates that general
anesthesia depends on speci¢c amino acid residues
that reside mostly in transmembrane helices [3,39^
41]. Most authors are careful to note that it is still
unknown whether such critical amino acids are part
of the anesthetic binding site or of the transducing
mechanism and to what degree the amino acid side-
chains are in contact with lipids [39^41]. Some 30
published dose-response curves for the e¡ects of gen-
eral anesthetics on tadpoles, on desensitization of the
nicotinic acetylcholine receptor and on various ion
channels have been analyzed for kinetic cooperativity
and found to be in all cases in the range of I90/I10,
2^15 (unpublished data). With multiple-site kinetics
as a tool, the lipid displacement mechanism therefore
appears to have general relevance. The cholesterol
activator site of the nicotinic acetylcholine receptor
also was within or very close to the lipid/protein
interface [15]. However, direct physical methods suit-
able for a distinction between the lipid/protein inter-
face and pure lipid or protein phases as target sites
for general anesthetics need to be developed. ESR
spectroscopy still presents great technical problems
[8]. In summary, the results presented here provide
good, albeit indirect, evidence for the lipid/protein
interface rather than protein or lipid alone as a target
site for general anesthetics.
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